A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease.

Trial Profile

A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors CSL; CSL Behring
  • Most Recent Events

    • 20 Nov 2013 Results assessing potential antiplatelet effects of CSL 112 presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 19 Nov 2013 Biomarker results presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 19 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top